Theravance Biopharma

TBPHPhase 3

South San Francisco, Cayman IslandsFounded 2014theravance.com

Theravance Biopharma is dedicated to transforming the treatment of specialty respiratory diseases through the discovery and development of 'Medicines that Make a Difference®'. The company achieved a significant milestone with the FDA approval and commercialization of YUPELRI® for COPD, which is co-commercialized with Viatris in the United States. With a strategic focus on insight, innovation, and managing uncertainty, Theravance Biopharma aims to create shareholder value by advancing its pipeline of organ-selective medicines for serious lung diseases. Its leadership team brings decades of experience from major pharmaceutical companies, guiding the company's integrated research, development, and commercial efforts.

Market Cap

$726.1M

Founded

2014

Focus

Small Molecules

AI Company Overview

Technology Platform

Platform for discovering and developing organ-selective medicines using multivalent pharmacology, aiming to maximize therapeutic effect at the target organ while minimizing systemic side effects.

Pipeline Snapshot

61 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
umeclidinium 62.5 µg and vilanterol 25 µg + Revefenacin 175 µg, Formoterol 20 µg...	COPD (Chronic Obstructive Pulmonary Disease)	Approved
Telavancin	End-Stage Renal Disease	Approved
ampreloxetine + Placebo	Symptomatic Neurogenic Orthostatic Hypotension	Phase 3
ampreloxetine + Placebo	Symptomatic Neurogenic Orthostatic Hypotension	Phase 3
Ampreloxetine + Placebo	Symptomatic Neurogenic Orthostatic Hypotension	Phase 3

Opportunities

Growth opportunities include expanding the market share of YUPELRI® in the underserved nebulized COPD segment and successfully advancing its pipeline of novel, lung-selective bispecific molecules into clinical trials for serious respiratory diseases with high unmet need.

Risk Factors

Key risks include heavy reliance on a single commercial product (YUPELRI), the high failure rate inherent in early-stage drug development for its pipeline candidates, and potential challenges in the co-commercialization partnership with Viatris.

Competitive Landscape

Primary competition comes from Sunovion's Lonhala Magnair in the nebulized COPD market and from major pharma companies (GSK, AstraZeneca, etc.) in the broader inhaler-based COPD market. Differentiation is based on YUPELRI's specific pharmacokinetic profile and the company's platform for developing lung-selective therapies.

Publications

Patents

Pipeline